Articles dans des revues avec comité de lecture (396)
  1. 169. Kerklaan, B. M., Mergui-Roelvink, M., Schellens, J. J., Diéras, V., Le Tourneau, C., Huitema, A. D., Rosing, H., Beijnen, J. J., Marreaud, S., Govaerts, A.-S., Awada, A., & Piccart-Gebhart, M. (2013). Erratum: Phase i study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023 (Cancer Chemother Pharmacol (2013) 71 (53-62)). Cancer chemotherapy and pharmacology, 71(2), 553. doi:10.1007/s00280-012-2064-y
  2. 170. Awada, A., Annemans, L., Broeckx, W., Pauwels, P., Simoens, S., Van Belle, S., Van Cutsem, E., Van Hoof, E., & De Greve, J. (2013). Stratified Medicine: A call for action. Belgian journal of medical oncology, 7(1), 15-19.
  3. 171. Kerklaan, B. M., Diéras, V., Le Tourneau, C., Mergui-Roelvink, M., Huitema, A. D., Rosing, H., Beijnen, J. J., Marreaud, S., Govaerts, A.-S., Piccart-Gebhart, M., Schellens, J. J., & Awada, A. (2013). Phase i study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023. Cancer chemotherapy and pharmacology, 71(1), 53-62. doi:10.1007/s00280-012-1972-1
  4. 172. Jacob, I., Payne, K., Awada, A., & Annemans, L. (2013). Stratified medicine: A call for action. Expert review of pharmacoeconomics & outcomes research, 13(3), 277-279. doi:10.1586/erp.13.29
  5. 173. Awada, A., Dirix, L., Manso Sanchez, L., Xu, B., Luu, T., Diéras, V., Hershman, D. L., Agrapart, V., Ananthakrishnan, R., & Staroslawska, E. (2013). Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Annals of oncology, 24(1), 109-116. doi:10.1093/annonc/mds284
  6. 174. Metzger-Filho, O., Saini, K., Abdel Azim, H. H., Awada, A., & Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME), (2012). Prevention and management of major side effects of targeted agents in breast cancer. Critical reviews in oncology/hematology, 84 Suppl 1, e79-e85. doi:10.1016/j.critrevonc.2010.07.014
  7. 175. Gombos, A., Metzger-Filho, O., Dal Lago, L., & Awada, A. (2012). Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad? Investigational new drugs, 30(6), 2433-2442. doi:10.1007/s10637-012-9811-0
  8. 176. Farhat, F. S., Tfayli, A., Fakhruddin, N., Mahfouz, R., Otrock, Z. K., Alameddine, R. S., Awada, A., & Shamseddine, A. I. (2012). Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Critical reviews in oncology/hematology, 84(2), 149-160. doi:10.1016/j.critrevonc.2012.02.012
  9. 177. Lalami, Y., Specenier, P. M., Awada, A., Lacombe, D., Liberatoscioli, C., Fortpied, C., El-Hariry, I., Bogaerts, J., Andry, G., Langendijk, J. A., & Vermorken, J. B. (2012). EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma. Radiotherapy and oncology, 105(2), 238-240. doi:10.1016/j.radonc.2012.08.006
  10. 178. Akasbi, Y., Awada, A., Arifi, S., Mellas, N., & El Mesbahi, O. (2012). Non-HIV Kaposi's sarcoma: a review and therapeutic perspectives. Bulletin du cancer, 99(10), 92-99. doi:10.1684/bdc.2012.1636
  11. 179. Porta, C., Tortora, G., Linassier, C., Papazisis, K., Awada, A., Berthold, D., Maroto, J. P., Powles, T. J., & De Santis, M. (2012). Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement. Medical oncology, 29(3), 1896-1907. doi:10.1007/s12032-011-0016-8
  12. 180. Leboulleux, S., Bastholt, L., Krause, T., de la Fouchardiere, C., Tennvall, J., Awada, A., Gómez, J. M., Bonichon, F., Leenhardt, L., Soufflet, C., Licour, M., & Schlumberger, M. J. (2012). Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet oncology, 13(9), 897-905. doi:10.1016/S1470-2045(12)70335-2
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>